Related Experiment Video

Updated: May 15, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Decoding the Raf-Mek-Erk-Rsk pathway in prostate cancer: from molecular mechanisms to clinical opportunities

Nick R Waldron1,2, Diogo Silva1,2, Daniel Westaby1,3

  • 1The Institute of Cancer Research, London, UK.

British Journal of Cancer
|May 13, 2026
PubMed

Insights

Advanced prostate cancer shows activation of the RAF-MEK-ERK-RSK pathway, crucial for cancer progression. Targeting this pathway is challenging due to a lack of predictive biomarkers and unique activation mechanisms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Advanced prostate cancer is a significant cause of mortality in the UK.
  • Clinically actionable molecular subtypes are largely absent in prostate cancer, unlike some other cancers.
  • The RAF-MEK-ERK-RSK signaling cascade is frequently activated in prostate cancer, with activation increasing as the disease progresses.

Purpose of the Study:

  • To investigate the role of the RAF-MEK-ERK-RSK pathway in prostate cancer progression.
  • To understand the mechanisms of RAF-MEK-ERK-RSK pathway activation in prostate cancer.
  • To explore the potential of targeting this pathway for prostate cancer treatment.

Main Methods:

  • Review of existing studies on RAF-MEK-ERK-RSK pathway activation in prostate cancer.
  • Analysis of mechanisms driving pathway activation, including paracrine and autocrine signaling.
  • Examination of the link between pathway activation and cancer cell proliferation and survival.

Main Results:

  • The RAF-MEK-ERK-RSK pathway is activated in prostate cancer through mechanisms beyond direct mutations.
  • Pathway activation is strongly associated with enhanced proliferative signaling and cell survival.
  • RAF-MEK-ERK-RSK pathway inhibitors have shown clinical utility in other cancers but not yet in prostate cancer.

Conclusions:

  • Targeting the RAF-MEK-ERK-RSK pathway in prostate cancer is hindered by a lack of predictive biomarkers and a complex activation landscape.
  • Future research must focus on identifying robust predictive biomarkers.
  • A deeper understanding of the fundamental biology of RAF-MEK-ERK-RSK activated prostate cancer is essential for successful therapeutic strategies.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...